The place of gliclazide MR in the treatment of type 2 diabetes mellitus. Clinical case

• Ekaterina N. Dudinskaya
• Kristina O. Chepygova

Abstract

The prevalence of type 2 diabetes mellitus (T2DM) represents a significant, pressing medical concern. Over 643 million individuals will grapple with T2DM by the year 2030, and the availability of effective and safe medications is one of the priorities of humanity. However, the limited accessibility and high prices of modern glucose-lowering therapies as well as average level of glucose-lowering effectiveness serve as barriers in the battle against T2DM complications and in achieving personalized glycemic goals. Amidst these challenges, second-generation sulfonylurea drugs (SUs) continue to hold relevance and garner interest. Gliclazide MR 60 mg stands out as a cost-effective alternative within this category, capturing the attention of healthcare providers for its established efficacy and favorable safety profile. Notably, original gliclazide MR not only proves effective in lowering glycated hemoglobin levels (by approximately 1.5–2%), but also exhibits cardioprotective, nephroprotective, and hemovascular properties. Research affirms its unique impact on pancreatic β-cells, enhancing the initial peak of insulin secretion while minimizing the risk of hypoglycemic episodes compared to other SUs. Additionally, the original gliclazide MR offers ease of dosage titration, making it an appealing treatment choice for a broad spectrum of T2DM patients.

Keywords: type 2 diabetes mellitus; gliclazide MR; sulfonylureas; hypoglycemia; old age

References

1. Sun H., Saeedi P., Karuranga S., Pinkepank M., Ogurtsova K., Duncan B.B., et al. Erratum to «IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045» [Diabetes Res. Clin. Pract. 183 (2022) 109119]. Diabetes Res Clin Pract. 2023; 204: 110945. DOI: https://doi.org/10.1016/j.diabres.2023.110945

2. Colagiuri S., Matthews D., Leiter L.A., Chan S.P., Sesti G., Marre M. The place of gliclazide MR in the evolving type 2 diabetes landscape: a comparison with other sulfonylureas and newer oral antihyperglycemic agents. Diabetes Res Clin Pract. 2018; 143: 1–14. DOI: https://doi.org/10.1016/j.diabres.2018.05.028

3. Tomlinson B., Li Y.H., Chan P. Evaluating gliclazide for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother. 2022; 23 (17): 1869–77. DOI: https://doi.org/10.1080/14656566.2022.2141108

4. Khunti K., Hassanein M., Lee M.K., Mohan V., Amod A. Role of gliclazide MR in the management of type 2 diabetes: report of a symposium on real-world evidence and new perspectives. Diabetes Ther. 2020; 11 (suppl 2): 33–48. DOI: https://doi.org/10.1007/s13300-020-00833-x

5. Schramm T.K., Gislason G.H., Vaag A., Rasmussen J.N., Folke F., Hansen M.L., et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011; 32 (15): 1900–8. DOI: https://doi.org/10.1093/eurheartj/ehr077

6. Simpson S.H., Lee J., Choi S., Vandermeer B., Abdelmoneim A.S., Featherstone T.R. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol. 2015; 3 (1): 43–51. DOI: https://doi.org/10.1016/S 2213-8587(14)70213-X

7. Rados D.V., Pinto L.C., Remonti L.R., Leitão C.B., Gross J.L. The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med. 2016; 13 (4): e1001992.

8. Shestakova M.V., Vikulova O.K. The results of open observational trial DIAMOND. Sakharniy diabet [Diabetes Mellitus]. 2011; 14 (3): 96–102. DOI: https://doi.org/10.14341/2072-0351-6232 (in Russian)

9. Maloney A., Rosenstock J, Fonseca V. A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: comparison of treatment effects at therapeutic doses. Clin Pharmacol Ther. 2019; 105 (5): 1213–23. DOI: https://doi.org/10.1002/cpt.1307

10. Hassanein M., Al Sifri S., Shaikh S., Abbas Raza S., Akram J., Pranoto A., et al. A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN. Diabetes Res Clin Pract. 2020; 163: 108154.

11. Dedov I.I., Shestakova M.V., Vikulova O.K., et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Sakharniy diabet [Diabetes Mellitus]. 2023; 26 (2): 104–23. DOI: https://doi.org/10.14341/DM13035 (in Russian)

12. Standards of specialized diabetes care (11th edition). In: I.I. Dedov, M.V. Shestakova, A. Yu. Mayorov (eds). Moscow, 2023. DOI: https://doi.org/10.14341/DM13042 (in Russian)

13. Bonora E., Trombetta M., Dauriz M., Travia D., Cacciatori V., Brangani C., et al. Chronic complications in patients with newly diagnosed type 2 diabetes: prevalence and related metabolic and clinical features: the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 9. BMJ Open Diabetes Res Care. 2020; 8 (1): e001549. DOI: https://doi.org/10.1136/bmjdrc-2020-001549

14. Honigberg M.C., Zekavat S.M., Pirruccello J.P., Natarajan P., Vaduganathan M. Cardiovascular and kidney outcomes across the glycemic spectrum: insights from the UK Biobank. J Am Coll Cardiol. 2021; 78 (5): 453–64. DOI: https://doi.org/10.1016/j.jacc.2021.05.004

15. Laiteerapong N., Ham S.A., Gao Y., Moffet H.H., Liu J.Y., Huang E.S., et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care. 2019; 42 (3): 416–26. DOI: https://doi.org/10.2337/dc17-1144

16. Visseren F.L.J., Mach F., Smulders Y.M., Carballo D., Koskinas K.C., Bäck M., et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42 (34): 3227–37. DOI: https://doi.org/10.1093/eurheartj/ehab484

17. Zoungas S., de Galan B.E., Ninomiya T., Grobbee D., Hamet P., Heller S., et al.; ADVANCE Collaborative Group. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care. 2009; 32 (11): 2068–74. DOI: https://doi.org/10.2337/dc09-0959

18. Seino S., Takahashi H., Takahashi T., Shibasaki T. Treating diabetes today: a matter of selectivity of sulphonylureas. Diabetes Obes Metab. 2012; 14 (10): 9–13. DOI: https://doi.org/10.1111/j.1463-1326.2011.01507.x

19. Shamkhalova M.S., Sukhareva O.Y. Early intensification of therapy for type 2 diabetes mellitus and achievement of the target level of glycohemoglobin HbA1c are necessary factors to reduce the risk of micro- and macrovascular complications. Sakharniy diabet [Diabetes Mellitus]. 2023; 26 (4): 343–51. DOI: https://doi.org/10.14341/DM13079 (in Russian)

20. Leiter L.A., Shestakova M.V., Satman I. Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial. Diabetol Metab Syndr. 2018; 10 (1): 30. DOI: https://doi.org/10.1186/s13098-018-0331-8

21. Zaccardi F., Jacquot E., Cortese V., Tyrer F., Seidu S., Davies M.J., et al. Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2020; 22 (12): 2417–26. DOI: https://doi.org/10.1111/dom.14169

22. Trubitsyna N.Р., Shestakova M.V. Review of the results of the EASYDia international observational study. The effect of dose titration of diabeton MR on the effectiveness of treatment of type 2 diabetes. Sakharniy diabet [Diabetes Mellitus]. 2019; 22 (2): 159–64. DOI: https://doi.org/10.14341/DM10185 (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)